Quarterly ResultApr 28, 2026, 06:32 AM
ZBH Q1 Net Sales $2.087B, EPS $1.22; Raises FY26 Adj. EPS Guidance
AI Summary
Zimmer Biomet Holdings, Inc. reported strong first-quarter 2026 financial results, with net sales increasing 9.3% to $2.087 billion and diluted EPS rising 34.1% to $1.22. Adjusted diluted EPS grew 15.5% to $2.09. The company also updated its full-year 2026 financial guidance, raising its adjusted EPS expectations. These results reflect healthy end markets and momentum from new product launches.
Key Highlights
- Q1 2026 net sales increased 9.3% to $2.087 billion (6.8% constant currency, 2.9% organic constant currency).
- Q1 2026 diluted EPS was $1.22, a 34.1% increase; adjusted diluted EPS was $2.09, up 15.5%.
- Raised full-year 2026 adjusted diluted EPS guidance to $8.40-$8.55 from $8.30-$8.45.
- Generated $359.4 million in operating cash flow and $245.9 million in free cash flow.
- Completed $250 million of share repurchases during Q1 2026.
- S.E.T. product category sales grew 19.5% to $562.2 million in Q1 2026.
- Knees sales increased 4.5% to $828.6 million and Hips sales rose 5.7% to $524.1 million.
- Completed enrollment in mBôs robotic total knee arthroplasty system clinical study in India.